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Background
Vertebroplasty has become a common treatment for painful osteoporotic vertebral 
fractures, but there is limited evidence to support its use.
Methods
We performed a multicenter, randomized, double-blind, placebo-controlled trial in 
which participants with one or two painful osteoporotic vertebral fractures that were 
of less than 12 months’ duration and unhealed, as confirmed by magnetic resonance 
imaging, were randomly assigned to undergo vertebroplasty or a sham procedure. 
Participants were stratified according to treatment center, sex, and duration of symp-
toms (<6 weeks or ≥6 weeks). Outcomes were assessed at 1 week and at 1, 3, and 
6 months. The primary outcome was overall pain (on a scale of 0 to 10, with 10 being 
the maximum imaginable pain) at 3 months.
Results
A total of 78 participants were enrolled, and 71 (35 of 38 in the vertebroplasty group 
and 36 of 40 in the placebo group) completed the 6-month follow-up (91%). Verte-
broplasty did not result in a significant advantage in any measured outcome at any 
time point. There were significant reductions in overall pain in both study groups 
at each follow-up assessment. At 3 months, the mean (±SD) reductions in the score 
for pain in the vertebroplasty and control groups were 2.6±2.9 and 1.9±3.3, respec-
tively (adjusted between-group difference, 0.6; 95% confidence interval, −0.7 to 1.8). 
Similar improvements were seen in both groups with respect to pain at night and 
at rest, physical functioning, quality of life, and perceived improvement. Seven in-
cident vertebral fractures (three in the vertebroplasty group and four in the placebo 
group) occurred during the 6-month follow-up period.
Conclusions
We found no beneficial effect of vertebroplasty as compared with a sham procedure 
in patients with painful osteoporotic vertebral fractures, at 1 week or at 1, 3, or 
6 months after treatment. (Australian New Zealand Clinical Trials Registry num-
ber, ACTRN012605000079640.)
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Osteoporotic vertebral fractures are a common cause of pain and disabil-ity and are associated with increased mor-
tality.1 Approximately 750,000 new vertebral frac-
tures occur in the United States each year,2 and 
among people who are older than 50 years of age, 
up to a quarter of them will have at least one ver-
tebral fracture in their lifetime.3 Although most 
fractures heal within a few months, some people 
have pain and disability that fail to respond to con-
servative therapy, and some require hospitalization, 
long-term care, or both.4 Therefore, interventions 
that effectively manage pain and shorten recovery 
time would be of great benefit.
Vertebroplasty, the percutaneous injection of 
polymethylmethacrylate (PMMA) into the affected 
vertebral body, has been advocated as a treatment 
for painful osteoporotic vertebral fractures.5,6 Ob-
servational studies suggest that there is an im-
mediate and sustained reduction in pain after this 
procedure is performed,5 but data from high-
quality randomized, controlled trials are lacking. 
The best currently available evidence for the effi-
cacy of vertebroplasty comes from one random-
ized, open trial involving 34 patients7 and two 
quasi-experimental, open, controlled, before–after 
studies that compared vertebroplasty with conser-
vative treatment.8,9 Although each study showed 
an early benefit of vertebroplasty, methodologic 
weaknesses cast doubt on the findings. In par-
ticular, the lack of blinding and the lack of a true 
sham control raise concern that the observed ben-
efits reflected a placebo response, an effect that 
may be magnified with an invasive procedure.10 
The same caveat applies to a recently published, 
open, randomized trial of balloon kyphoplasty, a 
procedure in which a balloon is used to inflate the 
affected vertebral body in order to compact the 
bone and push the end plates apart before the void 
is filled with bone cement.11
Despite evidence that is acknowledged to be 
inadequate as a basis for justifying reimbursement, 
public institutions have recommended reimburse-
ment for vertebroplasty.12,13 A recent position 
statement from various American radiologic and 
neurologic surgical societies also recommended 
funding the procedure.6 These endorsements have 
resulted in a dramatic increase in the number of 
vertebroplasties performed.14,15 For example, an 
examination of aggregate fee-for-service data from 
U.S. Medicare enrollees for the period from 2001 
through 2005 showed that the rate of vertebro-
plasties performed during that time almost dou-
bled, from 45.0 to 86.8 per 100,000 enrollees.14 
There are also reports of repeat procedures for 
unrelieved pain at previously treated vertebral lev-
els16 and of the prophylactic use of vertebroplasty 
in normal vertebrae that were deemed to be at high 
risk for fracture.17
Not only is the short-term efficacy of vertebro-
plasty unproven, but there are also several uncon-
trolled studies suggesting that vertebroplasty may 
increase the risk of subsequent vertebral fractures, 
particularly in vertebrae that are adjacent to treated 
levels, sometimes after cement has leaked into the 
adjacent disk18; controlled studies have shown 
conflicting results.8,9 Currently, there are insuffi-
cient data to estimate the true risk of subsequent 
vertebral fracture after vertebroplasty.18
Me thods
Study Design
We performed a randomized, parallel-group, pla-
cebo-controlled trial to determine the short-term 
efficacy and safety of vertebroplasty for alleviat-
ing pain and improving physical functioning in 
persons with painful osteoporotic vertebral frac-
tures. The protocol has been reported previously.19 
The participants, investigators (other than the ra-
diologists performing the procedures), and out-
come assessors were unaware of the group assign-
ments. A 2-year follow-up period was planned. 
Enrollment commenced in April 2004 and con-
cluded at the end of October 2008, and the fol-
low-up period will end in October 2010. The human 
research ethics committee at each participating 
center approved the study, and all participants pro-
vided written informed consent. Cook Australia 
provided partial grant support but had no role in 
the design of the trial, the collection or analysis 
of the data, the preparation of the manuscript, or 
the decision to submit the manuscript for publi-
cation.
Participants
Participants were recruited from the practices of 
general practitioners and specialists and from hos-
pital inpatient and emergency departments. In-
clusion criteria were the presence of back pain of 
no more than 12 months’ duration and the pres-
ence of one or two recent vertebral fractures, de-
fined as vertebral collapse of grade 1 or higher 
according to the grading system of Genant et al.20 
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(in which vertebral collapse is graded on a scale 
of 0 to 3, with higher numbers indicating greater 
vertebral collapse), and edema, a fracture line, or 
both within the vertebral body on magnetic reso-
nance imaging (MRI).19 The presence of bone mar-
row edema indicates an acute fracture.21
The exclusion criteria were the presence of more 
than two recent vertebral fractures, spinal cancer, 
neurologic complications, osteoporotic vertebral 
collapse of greater than 90%, fracture through or 
destruction of the posterior wall, retropulsed bony 
fragment or bony fragments impinging on the 
spinal cord, medical conditions that would make 
the patient ineligible for emergency decompres-
sive surgery if needed, previous vertebroplasty, 
inability to give informed consent, and a likeli-
hood of noncompliance with follow-up.
Eligible participants were randomly assigned in 
permuted blocks of 4 and 6, according to comput-
er-generated random numbers, to undergo either 
vertebroplasty or a sham procedure. Participants 
were stratified according to treatment center, sex, 
and duration of symptoms (<6 weeks or ≥6 weeks). 
To ensure concealment of the assigned interven-
tion, the treating radiologist obtained the opaque, 
sealed envelope containing the participant’s as-
signed intervention from the site’s receptionist just 
before the procedure was performed. Only the 
receptionist had access to the site’s assignment 
schedule. Neither the receptionist nor the treating 
radiologist had any other role in the trial.
Interventions
There were four participating sites, and experienced 
interventional radiologists performed all proce-
dures. All the radiologists had undertaken formal 
training in vertebroplasty, had appropriate certi-
fication, and were actively performing the proce-
dure. All the radiologists strictly adhered to a de-
tailed, standardized protocol. Care was taken to 
ensure that participants remained unaware of their 
assigned intervention.
For percutaneous vertebroplasty, the left pedi-
cle of the fracture site was identified with the use 
of a metallic marker. A 25-gauge needle was used 
to infiltrate the skin overlying the pedicle, and a 
23-gauge needle was used to infiltrate the perios-
teum of the posterior lamina. An incision was 
made in the skin, and a 13-gauge needle was 
placed posterolaterally relative to the eye of the 
pedicle. Gentle tapping guided the needle through 
the pedicle into the anterior two thirds of the frac-
tured vertebral body. Anterior–posterior and lat-
eral images were recorded with the needle in the 
correct position.
Prepared PMMA (approximately 3 ml) was 
slowly injected into the vertebral body, and satis-
factory infiltration of the vertebral body was con-
firmed radiographically. A bipedicular approach 
was used only if there was inadequate instillation 
of cement with the unipedicular approach. Injec-
tion was stopped when substantial resistance was 
met or when the cement reached the posterior 
quarter of the vertebral body; injection was also 
stopped if cement leaked into extraosseous struc-
tures or veins. All participants in the vertebro-
plasty group received cephalothin, administered 
intravenously immediately after PMMA injection.
Participants who were assigned to the sham 
intervention underwent the same procedures as 
those in the vertebroplasty group up to the inser-
tion of the 13-gauge needle to rest on the lamina. 
The central sharp stylet was then replaced with a 
blunt stylet. To simulate vertebroplasty, the verte-
bral body was gently tapped, and PMMA was pre-
pared so that its smell permeated the room.
After the intervention, all participants received 
usual care. Treatment decisions were made at the 
discretion of the treating physician, who received 
up-to-date guidelines on the management of os-
teoporosis. Analgesia was given according to stan-
dard practice, and its use was recorded.
Outcome Assessment
Baseline data, which were collected by a blinded 
assessor, included sex, birth date, height, weight, 
risk factors for osteoporosis, smoking status and 
alcohol use, medication use, history of fractures, 
measurement of bone mineral density (current or 
within the previous year), and the nature of the ver-
tebral fractures.20 At baseline, each participant also 
underwent the Up and Go test, which measures the 
time required to rise from a standard arm chair, 
walk 3 m, turn around, return to the chair, and sit 
down again.22 All participants were evaluated with 
the use of mailed questionnaires at 1 week and 
1, 3, and 6 months after the procedure.
The primary outcome was the score for over-
all pain (over the course of the previous week) as 
measured on a scale of 0 to 10 (with 0 indicating 
no pain, 10 indicating the maximum imaginable 
pain, and 1.5 as the minimal clinically important 
difference).23,24 Secondary outcomes included qual-
ity of life, as measured with the use of the Quality 
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of Life Questionnaire of the European Founda-
tion for Osteoporosis (QUALEFFO), a 41-item ver-
tebral-fracture–specific and osteoporosis-specific 
questionnaire (in which scores range from 0 to 
100, with lower scores indicating a better qual-
ity of life)25; the Assessment of Quality of Life 
(AQoL) questionnaire, a well-validated instrument 
that is sensitive to changes in the frail elderly 
(scores range from 0 to 1, with 1 indicating per-
fect health and 0.06 representing the minimal 
clinically important difference)26; and the Euro-
pean Quality of Life–5 Dimensions (EQ–5D) scale 
(scores range from 0 to 1, with 1 indicating perfect 
health and 0.074 representing the minimal clini-
cally important difference).27 Other secondary out-
comes included the scores for pain at rest and 
pain in bed at night (on a scale of 0 to 10, with 
higher scores indicating more pain); and the score 
on a modified 23-item version of the Roland–
Morris Disability Questionnaire (RDQ, in which 
scores range from 0 to 23, with higher numbers 
indicating worse physical functioning, and 2 to 
3 points representing the minimal clinically im-
portant difference).28
Perceived recovery with respect to pain, fatigue, 
and overall health was measured on 7-point ordi-
nal scales ranging from “a great deal worse” to 
“a great deal better.” Responses of “moderately 
better” or “a great deal better” were classified as 
successful outcomes. Adverse events, including 
incident clinical fractures, were assessed at each 
time point with the use of open-ended questions.
Statistical Analysis
The primary end point was the score for overall 
pain at 3 months. We calculated that a sample of 
24 participants per group would be required for 
the study to have 80% power to show at least a 
2.5-unit advantage of vertebroplasty over placebo 
with respect to pain, with a standard deviation of 
3.0, based on a two-sided type 1 error rate of 5%. 
Although a change of 1.5 units on a scale that 
ranges from 0 to 10 is regarded as the minimal 
clinically important difference with respect to 
pain,24 published studies at the time the trial was 
designed showed that vertebroplasty conferred 
very large effects (e.g., more than 5 points on a 
10-point scale). We also calculated that a sample 
of 82 participants per group would be needed to 
show an increase by a factor of three in the risk 
of further vertebral fractures at 24 months.19 How-
ever, we terminated trial enrollment before reach-
ing the sample size for long-term outcomes be-
cause it became evident that this sample size would 
not be achieved within an acceptable period of 
time and that the study’s power was sufficient to 
address the primary aim. This decision was made 
without knowledge of any outcome results.
All analyses were performed according to the 
intention-to-treat principle. Baseline differences 
between the groups were assessed with the use of 
Student’s t-test or nonparametric tests, as appro-
priate. Changes from baseline to 1 week, 1 month, 
3 months, and 6 months in measures of pain 
and scores on the QUALEFFO, AQoL, RDQ, and 
EQ–5D were compared with the use of multiple 
linear regression analyses. Estimates of between-
group mean differences adjusted for baseline val-
ues and the stratification variables are presented, 
together with 95% confidence intervals. All results 
are presented as improvements from baseline.
We compared measures of a perceived success-
ful outcome (reports of feeling moderately better 
or a great deal better vs. no change or feeling 
worse) after vertebroplasty and after the sham 
procedure by calculating the relative risks at each 
time point, using log binomial regression.29 We 
performed similar analyses among participants 
who reported a reduction in pain that was greater 
than 2.5 units. All reported P values are two-sided 
and have not been adjusted for multiple testing. 
Analyses were performed with the use of Stata 
software version 10.0 (StataCorp).
R esult s
Of 468 potential participants, 78 met the inclusion 
criteria and were randomly assigned to a study 
group (38 to the vertebroplasty group and 40 to the 
placebo group). Figure 1 shows the number of par-
ticipants involved in the trial from assessment 
for eligibility through the 6-month follow-up. Two 
participants in the vertebroplasty group and one 
in the placebo group died during the follow-up 
period for reasons thought to be unrelated to the 
trial. At the 6-month assessment, complete data 
were available for 71 of the 78 participants (91%).
The baseline characteristics of the participants 
were similar in the two groups (Table 1; addi-
tional information on baseline characteristics can 
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33p9
78 Underwent baseline assessment and randomization (stratified 
according to center, sex, and duration of symptoms, <6 or ≥6 wk)
468 Patients were assessed for eligibility
390 Were excluded
248 Did not meet inclusion criteria
114 Did not have vertebral fracture
67 Had fracture >12-mo duration or did not
meet MRI criteria
24 Had no significant pain
10 Had MRI contraindication to vertebro-
plasty
10 Had >2 new fractures
8 Had other significant health problems
6 Had active cancer
4 Had dementia
1 Had uncorrectable coagulation disorder 
1 Had neurologic complications
2 Had significant trauma
1 Had previous vertebroplasty
141 Declined to participate
1 Died
38 Were assigned to vertebro-
plasty intervention
26 Were at Center 1
7 Were at Center 2
2 Were at Center 3
3 Were at Center 4
40 Were assigned to placebo
intervention
27 Were at Center 1
8 Were at Center 2
3 Were at Center 3
2 Were at Center 4
1 Was in the hospital for unrelated
reasons and was therefore unable
to complete 1-wk assessment
3 Did not return questionnaires
37 Underwent 1-wk assessment 37 Underwent 1-wk assessment
3 Did not return questionnaires
1 Died (acute myocardial infarction)
1 Did not return questionnaire
35 Underwent 1-mo assessment 38 Underwent 1-mo assessment
1 Died (chest infection)
1 Did not return questionnaire
1 Died (esophageal cancer)
1 Did not return questionnaire
2 Did not return questionnaires
36 Underwent 3-mo assessment 37 Underwent 3-mo assessment
1 Withdrew owing to illness
2 Did not return questionnaires
35 Underwent 6-mo assessment 36 Underwent 6-mo assessment
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Figure 1. Enrollment, Assigned Intervention, and Follow-up.
Patients who did not complete one interim assessment either because they did not return a questionnaire or, in one 
case, because of hospitalization for a reason unrelated to the study could be include  in subsequent assessments.
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be found in Table 1 in the Supplementary Appen-
dix, available with the full text of this article at 
NEJM.org). In most participants, one vertebral 
fracture was treated; seven participants in each 
group had a second vertebra treated. In the verte-
broplasty group, the mean (±SD) volume of cement 
injected in the vertebrae was 2.8±1.2 ml. Minimal 
leakage was recorded in the case of 14 partici-
pants (37%).
No significant differences between groups were 
seen in the primary outcome of overall pain at 
3 months. Mean reductions in the score for over-
all pain in the vertebroplasty and placebo groups 
were 2.6±2.9 and 1.9±3.3, respectively (adjusted 
between-group difference, 0.6; 95% confidence 
interval, −0.7 to 1.8) (Table 2 and Fig. 2). There 
were no significant between-group differenc es 
in any other outcomes, except for the total 
QUALEFFO score at 1 week, which favored the 
placebo group. Results for the subscales of the 
QUALEFFO, perceived successful outcome with 
respect to fatigue and overall health, and reports 
of more than a 2.5-unit reduction in pain scores 
are shown in Table 2 in the Supplementary Ap-
pendix.
The observed differences between groups were 
smaller than the minimal clinically important 
differences for all outcomes; the 95% confidence 
intervals indicated that the ranges of plausible dif-
ferences between groups were unlikely to have in-
cluded differences of any practical importance. 
The results of the unadjusted group comparisons 
Table 1. Baseline Characteristics of the Study Participants.*
Characteristic Vertebroplasty (N = 38) Placebo (N = 40)
Age — yr 74.2±14.0 78.9±9.5
Female sex — no. (%) 31 (82) 31 (78)
Duration of back pain — wk
Median 9.0 9.5 
Interquartile range 3.8–13.0 3.0–17.0
Duration of symptoms <6 wk — no. (%) 12 (32) 13 (32)
Body-mass index† 25.6±5.5 24.6±5.7
Duration of corticosteroid use — yr‡
Median 3.0 2.0
Interquartile range 0.3–10.8 0.3–12.5
Pain score§
Overall 7.4±2.1 7.1±2.3
At rest 4.5±2.3 4.8±2.8
In bed at night 4.8±3.0 3.6±3.2
QUALEFFO total score¶ 56.9±13.4 59.6±17.1
AQoL score‖ 0.33±0.25 0.27±0.26
RDQ score** 17.3±2.8 17.3±2.9
EQ–5D score†† 0.30±0.32 0.28±0.33
Timed Up and Go test — sec‡‡ 20.5±8.8 23.9±13.8
Medication for osteoporosis — no. (%)
Any 35 (92) 37 (92)
Calcium supplements 27 (71) 25 (62)
Vitamin D 14 (37) 18 (45)
Bisphosphonates 31 (82) 32 (80)
One or more previous vertebral fractures — no. (%) 18 (47) 21 (52)
Opioids for pain — no. (%) 30 (79) 34 (85)
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were qualitatively similar to the results of the ad-
justed comparisons (data not shown). Analysis 
with the use of a linear mixed-effect, repeated-
measures model to assess the constancy of the 
effect of vertebroplasty at 1 week and at 1, 3, and 
6 months also showed no significant differences 
between the groups over time (data not shown).
The results appeared to be consistent irrespec-
tive of the duration of symptoms (<6 weeks vs. ≥6 
weeks, or as a continuous measure), sex, treatment 
center, or presence or absence of previous vertebral 
fractures (P>0.10 for all assessments of interac-
tions). Use of opioids decreased over time, with no 
significant between-group differences: at 1 week, 
10 participants (3 in the vertebroplasty group and 
7 in the placebo group) had stopped taking opi-
oids; at 1 month, 13 (4 in the vertebroplasty group 
and 9 in the placebo group) had stopped; at 
3 months, 22 (11 in each group) had stopped; and 
at 6 months, 35 (17 in the vertebroplasty group 
and 18 in the placebo group) had stopped.
Seven participants (three in the vertebroplasty 
group and four in the placebo group) reported an 
incident clinical vertebral fracture within 6 months 
after the study intervention (Table 3). Three par-
ticipants (one in the vertebroplasty group and two 
in the placebo group) reported new rib fractures 
at 1 week. One participant in the vertebroplasty 
group did not receive intravenous cephalothin ow-
ing to multiple drug allergies, and an adjacent 
new fracture and osteomyelitis developed, neces-
sitating surgical drainage and antibiotic treatment 
Table 1. (Continued.)
Characteristic Vertebroplasty (N = 38) Placebo (N = 40)
T score for bone mineral density ≤2.5 — no./total no. (%)
Lumbar 21/34 (62) 21/28 (75)
Femoral neck 13/34 (38) 15/28 (54)
Severity of fracture — no./total no. of fractures (%)§§
Mild 13/45 (29) 12/47 (26)
Moderate 21/45 (47) 24/47 (51)
Severe 11/45 (24) 11/47 (23)
No. of vertebral bodies treated — no. (%)
One 31 (82) 33 (82)
Two 7 (18) 7 (18)
* Plus–minus values are means ±SD. There were no significant differences between the groups for any of the measured 
variables.
† The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡ The data are based on a total of 12 participants in the vertebroplasty group and 17 in the placebo group who reported 
using corticosteroids.
§ Pain was assessed on a scale of 0 to 10, with higher numbers indicating more pain and with 1.5 as the minimal clini-
cally important difference.
¶ Scores on the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO) range from 0 
to 100, with higher scores indicating worse quality of life.
‖ Scores on the Assessment of Quality of Life (AQoL) range from −0.04 to 1.0, with 1 indicating perfect health and 0.06 
representing the minimal clinically important difference.
** Scores on the Roland–Morris Disability Questionnaire (RDQ) range from 0 to 23, with higher scores indicating worse 
physical functioning and 2 to 3 points representing the minimal clinically important difference. Scores were available 
for 30 participants in the vertebroplasty group and 29 in the placebo group. This questionnaire was added to the pro-
tocol in June 2005 (to allow comparison with outcomes in another trial30).
†† Scores on the European Quality of Life–5 Dimensions (EQ–5D) questionnaire range from 0 to 1, with 1 indicating 
perfect health and 0.074 representing the minimal clinically important difference. Scores were available for 30 partici-
pants in the vertebroplasty group and 29 in the placebo group. This questionnaire was added to the protocol in June 
2005 (to allow comparison with outcomes in another trial30).
‡‡ The Up and Go test measures the time required to rise from a standard arm chair, walk 3 m, turn around, return to 
the chair, and sit down again.22 Results were available for 36 participants in the vertebroplasty group and 37 in the 
placebo group.
§§ The severity of the fracture was assessed according to the semiquantitative grading system of Genant et al.,20 on a 
scale of 0 to 3, with higher numbers indicating greater vertebral collapse.
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approximately 2 weeks after randomization, but 
this participant recovered fully.
Discussion
We found no beneficial effect of vertebroplasty 
over a sham procedure at 1 week or at 1, 3, or 
6 months among patients with painful osteoporo-
tic vertebral fractures. Overall scores on measures 
of pain improved modestly in both groups over 
time, as did scores for pain at rest and during the 
night, physical functioning, and quality of life, 
but there were no significant between-group dif-
ferences.
The finding of the lack of an observed benefit 
of vertebroplasty at all time points up to and in-
cluding 6 months is at odds with most, but not all, 
earlier reports. For example, one controlled be-
Table 2. Outcomes at 1 Week and at 1, 3, and 6 Months, According to Intervention Group.*
Outcome Measure 1 Week 1 Month
Change in 
Vertebroplasty 
Group
Change in 
Placebo  
Group
Adjusted Between-Group 
Mean Difference  
(95% CI)†
Change in 
Vertebroplasty 
Group
Change in  
Placebo  
Group
Adjusted Between-Group 
Mean Difference  
(95% CI)†
Pain score‡
Overall 1.5±2.5 2.1±2.8 −0.7 (−1.8 to 0.4) 2.3±2.6 1.7±3.3 0.5 (−0.8 to 1.7)
At rest 0.8±3.0 1.3±3.9 −0.2 (−1.5 to 1.1) 1.4±2.9 1.2±4.0 0.5 (−0.9 to 1.8)
In bed at night 0.9±2.7 0.4±2.8 −0.1 (−1.3 to 1.1) 1.9±2.8 0.5±3.3 0.8 (−0.5 to 2.1)
QUALEFFO total score§ −0.5±7.4 3.6±9.2 −4.0 (−7.8 to −0.2) 2.8±9.3 2.4±12.3 0.9 (−4.2 to 6.0)
AQoL score¶ 0.0±0.2 0.0±0.2 0.0 (−0.1 to 0.1) 0.0±0.2 0.1±0.3 0.0 (−0.1 to 0.1)
RDQ score‖ 1.8±5.0 4.0±6.8 −2.1 (−5.2 to 0.9) 4.4±6.6 3.1±6.8 1.7 (−1.8 to 5.2)
EQ–5D score** 0.1±0.3 0.1±0.3 0.0 (−0.1 to 0.2) 0.1±0.3 0.1±0.3 0.0 (−0.1 to 0.1)
Change in 
Vertebroplasty 
Group 
Change in 
Placebo  
Group 
Relative Risk 
(95% CI)
††
Change in  
Vertebroplasty 
Group 
Change in 
Placebo 
Group 
Relative Risk 
(95% CI)††
Perceived pain — no. (%)‡‡
Better 6 (16) 13 (35) 0.5 (0.2 to 1.1) 12 (34) 9 (24) 1.5 (0.7 to 3.0)
No change 26 (70) 23 (62) 21 (60) 20 (53)
Worse 5 (14) 1 (3) 2 (6) 9 (24)
* Plus–minus values are means ±SD. Values were calculated on the basis of 37 participants in each group at 1 week; 35 in the vertebro-
plasty group and 38 in the placebo group at 1 month; 36 and 37 in the two groups, respectively, at 3 months; and 35 and 36 in the two 
groups, respectively, at 6 months. CI denotes confidence interval.
† The between-group difference was calculated with the use of multiple linear regression analyses adjusted for stratification variables and 
baseline values. Positive values favor the vertebroplasty group.
‡ Pain was assessed on a scale of 0 to 10, with higher numbers indicating more pain and with 1.5 as the minimal clinically important diff-
erence.
§ Scores on the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO) range from 0 to 100, with higher scores 
indicating worse quality of life.
¶ Scores on the Assessment of Quality of Life (AQoL) questionnaire range from −0.04 to 1.0, with 1 indicating perfect health and 0.06 repre-
senting the minimal clinically important difference.
‖ Scores on the Roland–Morris Disability Questionnaire (RDQ) range from 0 to 23, with higher scores indicating worse physical functioning 
and 2 to 3 points representing the minimal clinically important difference. The values were calculated on the basis of 30 participants in the 
vertebroplasty group and 29 in the placebo group at each time point.
** Scores on the European Quality of Life–5 Dimensions (EQ–5D) questionnaire range from 0 to 1, with 1 indicating perfect health and 0.074 
representing the minimal clinically important difference. The values were calculated on the basis of 30 participants in the vertebroplasty 
group and 29 in the placebo group at each time point.
†† The relative risk is for the comparison of ”better” with “no change” or “worse” (with “better” defined a priori as being a successful out-
come).
‡‡ Pain was classified as “better” if the participant indicated that the pain was moderately or a great deal better than before the intervention 
and as “worse” if the pain was reported to be moderately or a great deal worse than before the intervention.
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fore–after study showed a difference favoring ver-
tebroplasty at 24 hours, but at 6 weeks, 6 months, 
and 12 months, measures of pain and physical 
functioning after vertebroplasty were similar to 
those after conservative therapy.8
In contrast to previous studies, ours was a ran-
domized trial that included a control group un-
dergoing a sham procedure and that had a study 
design in which participants, investigators (other 
than the interventional radiologists), and outcome 
assessors were unaware of the intervention as-
signment and in which no crossover was permit-
ted. The rate of attrition in our study was low (less 
than 10%).
It has been argued that performing a random-
ized, placebo-controlled trial of vertebroplasty is 
unnecessary and unethical in view of the pub-
lished results of numerous studies that suggest 
a benefit of vertebroplasty.31 Our results show — 
not for the first time32,33 — the hazards of rely-
ing on the results of uncontrolled or poorly con-
trolled studies to assess treatment efficacy. These 
studies tend to overestimate the treatment ben-
efit by failing to take into account the favorable 
natural history of the condition, the tendency for 
a regression to the mean, and the placebo re-
sponse to treatment, which may be amplified 
when the treatment is invasive.10,34 Raised expec-
tations of an invasive intervention may explain the 
effect of a sham procedure.33
It is unlikely that the negative results of our 
study were due to the inclusion of participants who 
were not likely to benefit from vertebroplasty. The 
participants were similar to those enrolled in pre-
vious controlled studies.7-9,28 However, selection 
bias cannot be entirely ruled out, since 30% of 
potentially eligible participants declined to par-
ticipate in the study. Vertebroplasty was not read-
ily available when our trial commenced, but reim-
bursement approval granted in November 2005 
prompted active promotion of the procedure.35 
Although our ability to assess potential effect 
modifiers was limited by the failure of the trial to 
show any overall benefit of vertebroplasty and by 
the study’s relatively small sample size, we found 
no evidence that the duration of pain modified 
the effect of treatment, and only two participants 
in each group had had symptoms for longer than 
6 months. Furthermore, consistent with previous 
controlled studies, all participants were required 
to have bone edema in the affected vertebrae on 
MRI, a finding that is reported to predict a ben-
3 Months 6 Months
Change in 
Vertebroplasty 
Group
Change in  
Placebo  
Group
Adjusted Between-Group 
Mean Difference 
(95% CI)†
Change in 
Vertebroplasty 
Group
Change in 
Placebo 
Group
Adjusted Between-Group 
Mean Difference 
(95% CI)†
2.6±2.9 1.9±3.3 0.6 (−0.7 to 1.8) 2.4±3.3 2.1±3.3 0.1 (−1.2 to 1.4)
1.4±3.4 1.5±3.7 0.1 (−1.1 to 1.4) 2.0±3.2 0.9±3.2 0.3 (−0.9 to 1.5)
1.6±2.9 0.8±3.4 0.2 (−0.9 to 1.3) 1.5±3.6 1.6±3.6 −0.2 (−1.6 to 1.1)
6.0±9.6 6.1±13.7 0.7 (−4.4 to 5.7) 6.4±13.4 6.1±13.4 0.6 (−5.1 to 6.2)
0.0±0.2 0.1±0.3 0.0 (−0.1 to 0.1) 0.0±0.3 0.1±0.3 0.1 (−0.1 to 0.2)
3.7±5.4 5.3±7.2 −1.5 (−4.8 to 1.7) 4.1±5.8 3.7±5.8 0.0 (−3.0 to 2.9)
0.2±0.3 0.2±0.4 0.0 (−0.1 to 0.2) 0.2±0.4 0.2±0.4 0.0 (−0.1 to 0.2)
Change in 
Vertebroplasty 
Group 
Change in 
Placebo  
Group 
Relative Risk 
(95% CI)††
Change in 
Vertebroplasty 
Group 
Change in 
Placebo  
Group 
Relative Risk 
(95% CI)††
14 (39) 12 (32) 1.2 (0.6–2.2) 16 (46) 15 (42) 1.1 (0.6 to 1.9)
19 (53) 18 (49) 12 (34) 16 (44)
3 (8) 7 (19) 7 (20) 5 (14)
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eficial response to treatment.21 Although a short 
but considerable learning curve for vertebroplasty 
has been described,36 it is also unlikely that this 
explains our negative results; our trial involved 
experienced interventional radiologists who were 
using standardized procedures. A 2-year follow-up 
for vertebral fracture is planned, but a sample 
larger than that in our trial will be needed in order 
for the study to have adequate power to assess 
the effect of vertebroplasty on this outcome.
In conclusion, our trial showed no significant 
benefit of vertebroplasty over a sham procedure 
during 6 months of follow-up among patients with 
recent osteoporotic vertebral fractures. These find-
ings call into question the use of vertebroplasty 
for such patients.
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Table 3. Number of Incident Clinical Fractures and Adverse Effects Reported at 1 Week and at 1, 3, and 6 Months.*
Event Vertebroplasty Placebo
1 wk 1 mo 3 mo 6 mo Total 1 wk 1 mo 3 mo 6 mo Total
Incident fracture
Vertebra 1 1 1 3 3 1 4
Hip 1 1
Rib 1 1 2 2 2 4
Pelvis 1 1
Osteomyelitis 1 1
Tightness in the back or rib cage 1 1 2 2
Pain or burning in thigh or leg 3 1 4 1 1 2
Stomach pain 1 1 2 1 1
Increased pain or muscle cramping around 
puncture site
1 1 2 1 1
Chest pain 3 3
* An incident clinical fracture was defined as a fracture that was found on investigation after a patient presented  
with pain.
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